Ignite Creation Date:
2025-12-24 @ 2:59 PM
Ignite Modification Date:
2025-12-29 @ 1:28 PM
Study NCT ID:
NCT00196859
Status:
COMPLETED
Last Update Posted:
2014-07-17
First Post:
2005-09-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study in Elderly Patients With Early Breast Cancer (ICE)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077557', 'term': 'Ibandronic Acid'}, {'id': 'D000069287', 'term': 'Capecitabine'}], 'ancestors': [{'id': 'D004164', 'term': 'Diphosphonates'}, {'id': 'D063065', 'term': 'Organophosphonates'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1500}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2004-06'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-08', 'completionDateStruct': {'date': '2014-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-07-16', 'studyFirstSubmitDate': '2005-09-12', 'studyFirstSubmitQcDate': '2005-09-12', 'lastUpdatePostDateStruct': {'date': '2014-07-17', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2005-09-20', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Any local or distant relapse of breast cancer, any second malignancy, and any death irrespective of its cause'}], 'secondaryOutcomes': [{'measure': 'Any death related and not-related to breast cancer'}, {'measure': 'Any premature treatment discontinuation of capecitabine or ibandronate'}, {'measure': 'Any grade II to grade IV AE specified to serious or non serious events'}, {'measure': 'Every bone fracture, bone surgery, new diagnosis of osteoporosis'}, {'measure': 'Completed months of i.v. or p.o. treatment with ibandronate'}, {'measure': 'Frequency of changes of preference of Ibandronate application'}, {'measure': 'Evaluation according to EORTC Q 30'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Early Breast Cancer in elderly Patients', 'Ibandronate plus/minus Capecitabine in elderly patients'], 'conditions': ['Breast Cancer']}, 'referencesModule': {'references': [{'pmid': '37797387', 'type': 'DERIVED', 'citation': 'Schmidt M, Nitz U, Reimer T, Schmatloch S, Graf H, Just M, Stickeler E, Untch M, Runnebaum I, Belau A, Huober J, Jackisch C, Hofmann M, Krocker J, Nekljudova V, Loibl S; GBG/AGO-B, NOGGO/WSG study groups. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. Eur J Cancer. 2023 Nov;194:113324. doi: 10.1016/j.ejca.2023.113324. Epub 2023 Sep 7.'}, {'pmid': '34037241', 'type': 'DERIVED', 'citation': 'Hoon SN, Lau PK, White AM, Bulsara MK, Banks PD, Redfern AD. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database Syst Rev. 2021 May 26;5(5):CD011220. doi: 10.1002/14651858.CD011220.pub2.'}], 'seeAlsoLinks': [{'url': 'http://www.germanbreastgroup.de', 'label': 'Click here for more information about this study: ICE Study'}]}, 'descriptionModule': {'briefSummary': 'This trial is done to determine the role of adjuvant chemotherapy with capecitabine in patients ≥ 65.', 'detailedDescription': "Title of the study:\n\nIbandronate with or without Capecitabine in Elderly Patients with Early Breast Cancer - (ICE Study)\n\nRationale:\n\nApproximately 50% of new diagnosis of early breast cancer is made in patients above the age of 65. As this age group has not been eligible for most trials in the past, the effect of adjuvant therapy is still unclear in elderly patients. The primary aim of this trial will be to determine the role of adjuvant chemotherapy with capecitabine in elderly patients. The high activity, acceptable toxicity and oral formulation of this compound especially meet the requirements of elderly patients.\n\nBisphosphonates are of established effectivity in treatment and prevention of osteoporosis. Furthermore, two studies have recently shown that adjuvant long term use of clodronate can reduce the risk of recurrence of breast cancer. The third generation bisphosphonate ibandronate will be given in this trial to all patients to prevent osteoporosis and recurrence from breast cancer, both conditions these patients are at risk. As the preference of elderly patients for intravenous or oral application is not known, the mode of application of ibandronate will be according to patients' choice and the preference and compliance will be a secondary endpoint.\n\nPrimary objective\n\nTo compare the event-free survival in elderly patients after local treatment for primary breast cancer treated with either ibandronate alone or ibandronate and capecitabine as adjuvant treatment\n\nSecondary objectives\n\nTo compare the overall survival between the two arms\n\nTo determine the compliance in both arms\n\nTo determine the toxicity in both arms\n\nTo determine the rate of bone-related events in hormone sensitive and insensitive disease (with or without endocrine therapy)\n\nTo determine the preference to oral or intravenous application of ibandronate\n\nTo assess quality of life\n\nTo compare a geriatric assessment by Charlson versus VES 13 score\n\nTertiary objective\n\nTo determine prognostic factors on tumor tissue collected from primary surgery and to correlate them with study treatment effect\n\nTo evaluate the prognostic impact of age, serum albumin, hemoglobin level, creatinine clearance, Charlson Score, VES-Score in a multivariate analysis for the prediction of treatment associated adverse events and limited life time expectancy"}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '65 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements.\n2. Histologically confirmed unilateral or bilateral primary carcinoma of the breast.\n3. Age at diagnosis ≥ 65 years\n4. Adequately surgical treatment with complete resection (Ro) of the tumor and \\> or = 10 axillary nodes. Sole sentinel node biopsy is allowed if the sentinel node shows no tumor involvement.\n5. Node positive disease irrespective of additional risk factors or node negative disease with at least one other risk factor (histologic tumor size \\> or = 2 cm, grade II or III, ER and PR negative)\n6. No evidence for distant metastasis after complete diagnostic work up\n7. Performance Status ECOG \\< or = 2\n8. Charlson Scale of \\< or = 2\n9. Estimated life expectancy of at least 5 years (irrespective of breast cancer diagnosis)\n10. The patient must be accessible for treatment and follow-up.\n\nExclusion Criteria:\n\n1. Known hypersensitivity reaction to the compounds or incorporated substances or known dihydropyrimidine dehydrogenase deficiency.\n2. Inadequate organ function including: Leucocytes \\< 3,5 G/l, Platelets \\< 100 G/l , Bilirubin 1.25 times above normal limits, Creatinine clearance calculated by the Cockroft-Gold formula of above 50 ml/min, uncompensated cardiac function, severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study\n3. Another primary malignancy with an event-free survival of \\< 5 years, except curatively treated basalioma of the skin\n4. Time since axillary dissection \\> 3 months\n5. Locally advanced, non-operable breast cancer\n6. Previous invasive breast carcinoma\n7. Previous treatment with cytotoxic agents for any reason\n8. Concurrent treatment with hormonal replacement therapy (treatment should be stopped before entering the trial).\n9. Previous treatment with bisphosphonates for osteoporosis is allowed, however this treatment has to be substituted by the trial medication\n10. Concurrent specific systemic anti-tumor treatment or treatment with experimental compounds within the last 6 months\n11. Concurrent treatment with other tumor specific experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.\n12. Concurrent treatment with virostatic agents like brivudine or analoga sorivudine, concurrent treatment with aminoglycosides\n13. Male patients'}, 'identificationModule': {'nctId': 'NCT00196859', 'briefTitle': 'Study in Elderly Patients With Early Breast Cancer (ICE)', 'organization': {'class': 'OTHER', 'fullName': 'GBG Forschungs GmbH'}, 'officialTitle': 'Ibandronate With or Without Capecitabine in Elderly Patients With Early Breast Cancer', 'orgStudyIdInfo': {'id': 'GBG 32'}, 'secondaryIdInfos': [{'id': 'BIG 4-04'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'A', 'description': 'Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs', 'interventionNames': ['Drug: Ibandronate']}, {'type': 'EXPERIMENTAL', 'label': 'B', 'description': 'Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6', 'interventionNames': ['Drug: Ibandronate, Capecitabine']}], 'interventions': [{'name': 'Ibandronate, Capecitabine', 'type': 'DRUG', 'description': 'Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6', 'armGroupLabels': ['B']}, {'name': 'Ibandronate', 'type': 'DRUG', 'description': 'Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs', 'armGroupLabels': ['A']}]}, 'contactsLocationsModule': {'locations': [{'zip': '41061', 'city': 'Mönchengladbach', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Prof. Dr. med. Ulrike Nitz', 'geoPoint': {'lat': 51.18539, 'lon': 6.44172}}], 'overallOfficials': [{'name': 'Ulrike Nitz, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Evangelisches Krankenhaus Bethesda, Mönchengladbach'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'GBG Forschungs GmbH', 'class': 'OTHER'}, 'collaborators': [{'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, {'name': 'AstraZeneca', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}